Stocklytics Platform
Asset logo for symbol SABSW
SAB Biotherapeutics
SABSW44
$0.05arrow_drop_down35.14%-$0.02
Penny Stock
Asset logo for symbol SABSW
SABSW44

$0.05

arrow_drop_down35.14%

Performance History

Chart placeholder
Key Stats
Open$0.07
Prev. Close$0.07
EPS0.29
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$0.00
LOWHIGH
Day Range0.05
0.09
52 Week Range0.01
0.18
Ratios
Revenue-
EPS0.29

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About SAB Biotherapeutics (SABSW)

SAB Biotherapeutics, Inc. (SABSW) is a biotechnology company that specializes in the development of human antibody therapeutics. The company's focus is on utilizing its proprietary DiversitAb™ platform to produce fully human antibodies in a rapid and cost-effective manner. These antibodies have the potential to treat a wide range of diseases, including infectious diseases, autoimmune disorders, and cancer. SABSW's innovative approach harnesses the power of transchromosomic cattle, which have been genetically engineered to produce human antibodies in their milk. This unique platform allows for the production of large quantities of antibodies with high specificity and potency.
One of the key advantages of SABSW's approach is its ability to rapidly respond to emerging infectious diseases. Traditional vaccine development can take years, but SABSW's platform enables the production of fully human antibodies within a matter of months. This speed and scalability provide a significant advantage in addressing global health threats such as pandemics. SABSW has demonstrated the effectiveness of its approach in preclinical studies, where its human antibody therapeutics have shown strong efficacy against multiple pathogens, including influenza, Ebola, Zika, and COVID-19.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Eddie Joe Sullivan Ph.D.
Headquarters
Sioux Falls
Employees
56
Exchange
NASDAQ
add SAB Biotherapeutics to watchlist

Keep an eye on SAB Biotherapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is SAB Biotherapeutics's (SABSW) price per share?

The current price per share for SAB Biotherapeutics (SABSW) is $0.05. The stock has seen a price change of -$0.03 recently, indicating a -35.15% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for SAB Biotherapeutics (SABSW)?

For SAB Biotherapeutics (SABSW), the 52-week high is $0.18, which is 260% from the current price. The 52-week low is $0.02, the current price is 212.5% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is SAB Biotherapeutics (SABSW) a growth stock?

SAB Biotherapeutics (SABSW) has shown an average price growth of -5.34% over the past three years. It has received a score of 85 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying SAB Biotherapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is SAB Biotherapeutics (SABSW) stock price performance year to date (YTD)?

As of the latest data, SAB Biotherapeutics (SABSW) has a year-to-date price change of 132.56%. Over the past month, the stock has experienced a price change of -27.33%. Over the last three months, the change has been 127.27%. Over the past six months, the figure is 25.63%.
help

Is SAB Biotherapeutics (SABSW) a profitable company?

SAB Biotherapeutics (SABSW) has a net income of -$42.19M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3.42K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$38.08M. Furthermore, the EBITDA is -$46.91M.
help

What is the market capitalization of SAB Biotherapeutics (SABSW)?

SAB Biotherapeutics (SABSW) has a market capitalization of $0. The average daily trading volume is 0.08, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level